Intensity therapeutics provides business update highlighting key achievements with lead drug candidate int230-6

The us fda, health canada, european medicines authority, and the australian therapeutic goods administration authorized the company's global, randomized phase 3 study (invincible-3) in metastatic soft tissue sarcoma twenty-three sites are currently contracted in the invincible 3 study, and several sites have treated patients seven swiss sites are activated in the phase 2 (invincible-4) study for early-stage, operable triple negative breast cancer ("tnbc"), and several patients have been treated shelton, conn. , jan. 10, 2025 /prnewswire/ -- intensity therapeutics, inc. ("intensity" or the "company") (nasdaq: ints), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announces a business update highlighting key achievements with its lead drug candidate int230-6.
INT Ratings Summary
INT Quant Ranking